

## COMMUNICATION OF OTHER RELEVANT INFORMATION

8th January 2024

Pursuant to the provisions of article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services (the "LMVSI") and other related provisions, ATRYS HEALTH, S.A. ("**ATRY**S" or the "**Company**"):

ATRY S announces that on 5 January 2024, it has executed the early redemption for the nominal amount of 25,000,000 euros of the Bonds issued by Atrys Health Internacional, S.A.U. under the Atrys Health Internacional, S.A.U. 2020 Fixed Income Programme (ISIN Code ES205503008).

As indicated in the Insider Trading Communication of 20 November 2023 (with registration number 2040 "[Atrys updates the earnings forecast as a result of the exit of Conversia from the scope of consolidation](#)"), following the execution of the sale of 75.01% of Professional Group Conversia, S.L. announced in the Communication of Other Material Information of 13 December 2023 (with registration number 25793 "[ATRY S announces the closing of the sale of 75.01% of Professional Group Conversia S.L.](#)") and the issue of contingent convertible bonds in the amount of 13.3 million euros announced via Inside Information Communication on 28 December 2023 (with registration number 2070 "[ATRY S announces the issue of convertible bonds in the amount of 13,300,000 euros](#)"), the company has proceeded to redeem a total of 43 million euros of debt, including the 25 million euros redeemed early from the Atrys Health Internacional, S.A.U. 2020 Fixed Income Programme indicated in this OIR.

Madrid, 8th January, 2024

Ms Isabel Lozano Fernández

Chief Executive Officer